Investigation of miR-26a-5p and miR-19a-3p expression levels in angiographically confirmed coronary artery disease

Neslihan Coban1, Aycan F Erkan2, Aybike Sena Ozuynuk-Ertugrul1,3

  • 1Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.

Acta Cardiologica
|June 28, 2023
PubMed
Abstract

Insights

Circulating miR-26a-5p levels are elevated in coronary artery disease (CAD) patients. Both miR-26a-5p and miR-19a-3p correlate with diabetes risk factors, suggesting potential as therapeutic targets for CAD.

Area of Science:

  • Cardiovascular Biology
  • Molecular Diagnostics
  • Biomarker Discovery

Background:

  • MicroRNAs (miRNAs) play a crucial role in cardiovascular diseases.
  • Previous studies indicated altered miR-26a-5p and miR-19a-3p expression in severe coronary atherosclerosis.
  • The specific roles of these miRNAs in coronary artery disease (CAD) require further investigation.

Purpose of the Study:

  • To analyze the expression of miR-26a-5p and miR-19a-3p in patients with angiographically confirmed CAD.
  • To evaluate the potential diagnostic value of these circulating miRNAs for CAD.
  • To explore the correlation of miRNA expression with clinical parameters and risk factors.

Main Methods:

  • Quantification of miR-26a-5p and miR-19a-3p using TaqMan miRNA assays and real-time PCR.
  • Comparison of miRNA expression between 50 CAD patients and 43 non-CAD controls.
  • Assessment of diagnostic value and correlation with clinical parameters, including diabetes risk factors.

Main Results:

  • miR-26a-5p expression was significantly increased in CAD patients compared to controls (p < 0.05).
  • Higher miR-26a-5p expression correlated with CAD presence, while higher miR-19a-3p expression was linked to increased diabetes frequency.
  • Both miRNAs showed significant correlations with diabetes risk factors like HbA1c, glucose levels, and BMI (p < 0.05).

Conclusions:

  • miR-26a-5p expression is altered in the presence of CAD.
  • miR-19a-3p expression differs in individuals with diabetes, and both miRNAs are associated with CAD risk factors.
  • These miRNAs represent potential therapeutic targets for CAD treatment.